Patent application number | Description | Published |
20120165503 | OXYNTOMODULIN ANALOGS - Peptide analogs of oxyntomodulin (OXM, glucagon-37), which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to act as a dual GLP-1/glucagon receptor (GCGR) agonistm are described. The peptide analogs are useful for treatment of metabolic disorders such as diabetes and obesity. | 06-28-2012 |
20130090286 | GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS - Modified glucagon peptides are disclosed having enhanced potency at the glucagon receptor relative to native glucagon. Further modification of the glucagon peptides by forming intramolecular bridges or the substitution of the terminal carboxylic acid with an amide group produces peptides exhibiting glucagon/GLP-1 receptor co-agonist activity. The solubility and stability of these high potency glucagon analogs can be further improved by modification of the polypeptides by pegylation, acylation, alkylation, substitution of carboxy terminal amino acids, C-terminal truncation, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 26 (GPSSGAPPPS), SEQ ID NO: 27 (KRNRNNIA) and SEQ ID NO: 28 (KRNR). | 04-11-2013 |
20140161826 | NON-SELF T-CELL EPITOPE FUSED TO AN ANTIBODY THAT RECOGNISES A TUMOUR-SPECIFIC CELL-SURFACE RECEPTOR AND USES THEREOF - A first composition comprising a ligand part being able to specifically bind to a target, the target being on a diseased cell of an organism, and an epitope part having a non-self epitope, or encoding a non-self epitope, the non-self epitope not naturally being encoded by the organism, wherein the target is internalized after forming a complex with the composition and the non-self epitope is presented on the cell surface of said diseased cell of an organism after internalization. | 06-12-2014 |
Patent application number | Description | Published |
20100075907 | NEUROMEDIN U RECEPTOR AGONISTS AND USES THEREOF - Neuromedin U receptor agonists for use in the treatment of metabolic disorders such as obesity and diabetes are disclosed. | 03-25-2010 |
20100092505 | Method for Shielding Functional Sites or Epitopes on Proteins - Methods of site-specifically shielding one or more binding sites within a polypeptide are disclosed, comprising attaching at least one small molecular weight, water-soluble polymer to said polypeptide such that the binding site is masked by said polymer. The shielding of a binding site (e.g., epitope) as per the disclosed methods acts to either eliminate or substantially reduce the biological response induced by the interaction between said binding site and its cognate receptor, helping to refocus the biological response toward unmasked portions of the polypeptide. Pharmaceutical products generated as per the methods described herein (e.g., polymer-modified antigens and vaccine compositions comprising them), as well as the use thereof, induce a specific immune response against unmasked portions of the polypeptides when directly introduced into living vertebrate tissue, preferably a mammalian host such as a human or a non-human mammal of commercial or domestic veterinary importance, generating selective immunoprotection in said mammal. | 04-15-2010 |
20100144617 | Oxyntomodulin Derivatives - Modified oxyntomodulin derivatives. Such derivatives can be used for the treatment of metabolic diseases such as diabetes and obesity. | 06-10-2010 |
20100305028 | CHOLESTEROL DERIVATIVES OF INHIBITORS OF VIRAL FUSION - The present invention relates to compounds comprising at least ten contigous amino acids of the HR2 domain of a Type 1 viral fusogenic protein of an enveloped virus, or a derivative thereof, attached at the C-terminal to cholesterol or a derivative thereof; or a pharmaceutically acceptable salt thereof which inhibit viral fusion. Thus compounds of the invention are useful to prevent or treat diseases caused by an enveloped virus. | 12-02-2010 |
20110046056 | APOA-1 PEPTIDE MIMETICS - The invention relates to peptide mimetics for treating disorders associated with hypercholesterolemia and cardio-vascular disease. In particular, the invention relates to peptides that mimic the activity of apolipoprotein A-I (Apo AI). | 02-24-2011 |
20110183902 | PHARMACEUTICAL COMPOSITION COMPRISING OXYNTOMODULIN DERIVATIVES AND A METHOD FOR REDUCING BODY WEIGHT USING THE COMPOSITION - Modified oxyntomodulin derivatives. Such derivatives can be used for the treatment of metabolic diseases such as diabetes and obesity. | 07-28-2011 |
20110301079 | NEUROMEDIN U RECEPTOR AGONISTS AND USES THEREOF - Neuromedin U receptor agonists for use in the treatment of metabolic disorders such as obesity and diabetes are disclosed. In particular, disclosed are neuromedin U receptor agonists that comprise neuromedin S (NMS). | 12-08-2011 |
20130150563 | LIPID-CONJUGATED ANTIBODIES - The present invention relates to novel lipid-conjugated antibodies for use in the treatment or the prevention of diseases, including but not limited to cancer, metabolic diseases including but not limited to hyperglycemia and diabetes, obesity, hypertension, hypercholesterolemia, allergy, asthma, Alzheimer's disease, and infectious diseases including but not limited to diseases caused by viruses, bacteria and fungi. | 06-13-2013 |
20130196903 | Multimeric Inhibitors of Viral Fusion and Uses Thereof - The present invention relates to novel multimeric inhibitors of viral entry into cells and their use for the prophylaxis and treatment of viral infections. | 08-01-2013 |
20140094405 | CHOLESTEROL DERIVATIVES OF INHIBITORS OF VIRAL FUSION - The present invention relates to compounds comprising at least ten contiguous amino acids of the HR2 domain of a Type 1 viral fusogenic protein of an enveloped virus, or a derivative thereof, attached at the C-terminal to cholesterol or a derivative thereof; or a pharmaceutically acceptable salt thereof which inhibit viral fusion. Thus compounds of the invention are useful to prevent or treat diseases caused by an enveloped virus. | 04-03-2014 |